CA1199371A - Ultrasonic enhancement of cardiac contractility synchronised with ecg event or defibrillation pulse - Google Patents
Ultrasonic enhancement of cardiac contractility synchronised with ecg event or defibrillation pulseInfo
- Publication number
- CA1199371A CA1199371A CA000416992A CA416992A CA1199371A CA 1199371 A CA1199371 A CA 1199371A CA 000416992 A CA000416992 A CA 000416992A CA 416992 A CA416992 A CA 416992A CA 1199371 A CA1199371 A CA 1199371A
- Authority
- CA
- Canada
- Prior art keywords
- ultrasound
- heart
- generating
- cardiac
- ultrasonic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000000747 cardiac effect Effects 0.000 title claims abstract description 20
- 230000001360 synchronised effect Effects 0.000 title description 3
- 238000002604 ultrasonography Methods 0.000 claims abstract description 50
- 239000000523 sample Substances 0.000 claims description 2
- 230000010247 heart contraction Effects 0.000 claims 1
- 210000000038 chest Anatomy 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 5
- 238000001356 surgical procedure Methods 0.000 abstract description 4
- 210000000779 thoracic wall Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 108091006112 ATPases Proteins 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ODPOAESBSUKMHD-UHFFFAOYSA-L 6,7-dihydrodipyrido[1,2-b:1',2'-e]pyrazine-5,8-diium;dibromide Chemical compound [Br-].[Br-].C1=CC=[N+]2CC[N+]3=CC=CC=C3C2=C1 ODPOAESBSUKMHD-UHFFFAOYSA-L 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000370685 Arge Species 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 101150072084 BCAM gene Proteins 0.000 description 1
- 101100342815 Caenorhabditis elegans lec-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000272470 Circus Species 0.000 description 1
- 239000005630 Diquat Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- POSKOXIJDWDKPH-UHFFFAOYSA-N Kelevan Chemical compound ClC1(Cl)C2(Cl)C3(Cl)C4(Cl)C(CC(=O)CCC(=O)OCC)(O)C5(Cl)C3(Cl)C1(Cl)C5(Cl)C42Cl POSKOXIJDWDKPH-UHFFFAOYSA-N 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- 101100496106 Mus musculus Clec2f gene Proteins 0.000 description 1
- 101100521345 Mus musculus Prop1 gene Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108700017836 Prophet of Pit-1 Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001862 defibrillatory effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- NQLVQOSNDJXLKG-UHFFFAOYSA-N prosulfocarb Chemical compound CCCN(CCC)C(=O)SCC1=CC=CC=C1 NQLVQOSNDJXLKG-UHFFFAOYSA-N 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 210000000518 sarcolemma Anatomy 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H31/00—Artificial respiration or heart stimulation, e.g. heart massage
- A61H31/004—Heart stimulation
- A61H31/006—Power driven
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00137—Details of operation mode
- A61B2017/00154—Details of operation mode pulsed
- A61B2017/00181—Means for setting or varying the pulse energy
- A61B2017/00185—Means for setting or varying the pulse height
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00137—Details of operation mode
- A61B2017/00154—Details of operation mode pulsed
- A61B2017/00181—Means for setting or varying the pulse energy
- A61B2017/0019—Means for setting or varying the pulse width
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00681—Aspects not otherwise provided for
- A61B2017/00694—Aspects not otherwise provided for with means correcting for movement of or for synchronisation with the body
- A61B2017/00703—Aspects not otherwise provided for with means correcting for movement of or for synchronisation with the body correcting for movement of heart, e.g. ECG-triggered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/02—Characteristics of apparatus not provided for in the preceding codes heated or cooled
- A61H2201/0207—Characteristics of apparatus not provided for in the preceding codes heated or cooled heated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/02—Characteristics of apparatus not provided for in the preceding codes heated or cooled
- A61H2201/0214—Characteristics of apparatus not provided for in the preceding codes heated or cooled cooled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5007—Control means thereof computer controlled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2230/00—Measuring physical parameters of the user
- A61H2230/04—Heartbeat characteristics, e.g. E.G.C., blood pressure modulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
- A61H23/02—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
- A61H23/0245—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with ultrasonic transducers, e.g. piezoelectric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
- A61N1/39—Heart defibrillators
- A61N1/3904—External heart defibrillators [EHD]
Abstract
TITLE
METHOD AND DEVICE FOR ENHANCEMENT OF CARDIAC CONTRACTILITY
INVENTORS
George V. Forester Alan J. Mortimer Orest Z. Roy ABSTRACT OF THE DISCLOSURE.
An apparatus for ultrasonic irradiation of the heart either when the chest is open after surgery or through the chest wall. It may also be used in conjunction with electrical defibrillation equipment or alone. The apparatus includes an EKG for detecting the heart beat, an ultrasonic generator and timing and pulsing circuits for providing timed pulses of ultrasound to coincide with selected events in the cardiac cycle.
METHOD AND DEVICE FOR ENHANCEMENT OF CARDIAC CONTRACTILITY
INVENTORS
George V. Forester Alan J. Mortimer Orest Z. Roy ABSTRACT OF THE DISCLOSURE.
An apparatus for ultrasonic irradiation of the heart either when the chest is open after surgery or through the chest wall. It may also be used in conjunction with electrical defibrillation equipment or alone. The apparatus includes an EKG for detecting the heart beat, an ultrasonic generator and timing and pulsing circuits for providing timed pulses of ultrasound to coincide with selected events in the cardiac cycle.
Description
Thls invention relates to prodllcl.ng an enhancelilent of cardlac contractili.ty throllgh the use of ultrcl.sourld.
More partlcularly, the presen~ LnvelltLoll provi(les a method of improving cardlac performallce by appLying ultra.so~ d to the heart Ltself, either ~nternal.ly from ~q catlleter plflce(l wit.llin tlle heart, by ultrasoundIrradiatiorl appl:Led orl tlle surface of the bocly, or by ultra.qourlcl irradla~
tion applied directly ln contact with the heart. Ultrasourld -Ls also applied in combination w:ith an electrical deEibril.lator or pacemakerO
~le tnvention also relates to a metllod for application of ultrasound for well defined and selectable periods o~ time arranged to colnci.de wlth critical events in the cardiac cycle~
In addition, the lnvention relates to a method ~or the applica-tion of ultrasound ~or weLl defined and selectab].e periods of time relat-ed to critical events in the process of electrical def.LbrillationO
When the ultrasolllld waves produced by the transducers are a~justed such that their energy traverses the heart Ltself, the action of the waves can exert their e~fect by creating microthermal heating, micro-circnlation changes, stirring, stab:Le cav.Ltat-lon, microstreami.ng, or chemical effects~ The differential heating i.s produced because of the knowll property of ultrasound to be ab.sorbed by tissues according to their viscosities. Thus, membrane organelles within the heart absorb more energy than cytoplasmic components. It is thus expected that the sarco-plasmic reti.culum belng an internally located organelle within the heart would absorb energy and be heated preferentially before cytopla.sm.
Similarly, the sarcolemllla and its internal projections - the transverse and longitudinal transverse system would also be heated more thall extra-ceilulAr areas and cytoplasm. ~ecause of the differential heating, one woul.d expect bLo].ogic actLvitLes associated with these membranous compon-ents to be stimulated.
Thus, we find a linear relatlonsllip between myocardial enhance-ment between ().2 watt/cm2 an(l 2.() W/cm2 SAT~ of ultrasound exposllre~
This implies that when energy from ultra~soulld is applied wlthin a range to increase diEferential heatillg wltllin the l-Lmits commensllrate wlth bio--loglc activity (<44C~ we call fiel.ectlvely improve myocardla:l. performance.
~ur experimelltal evidence fihows that a portlon o~ the ~ILtrasoulld e~ect 3~
is produced via an increase o~ thc e~f-Lclellcy oE the excLtat-Lon-colltrac-tion coupling ~ystem. ~econd'ly, ~he actlorl poten~lal of ultrasound irradLated cells indLcates an imE)rovemellt in calcium transfer across the membrane in the ylateau phase. Both of these Eacts suggest that ultra-sound modLfies ~arcolemmal (external muscle membrane) characterir;tlc6.
The ultrasolllld eFfects are complete1y reverslble as opposed to conven-tional drug therapies.
Tl1e changes irl the "act~on potent-Lal" characteristics are con-si~stent wLth tlle view that membrane properties and, hence, biologlc prop-1~) erties are temporarily modlEied by ultrasound. Such changes would alterthe sodium-potassium ATPase~ This is seen in the resting nonexcited heart muscle as a rapid hyperpo]arisatLon of the membrarle potential which can be interpreted as an Lncrease in the activity of the Na~-K~~ATPase of sarcolemma. Seconclly, the rapid increase in the overshoot of the car-diac "action potential" with ultrasound point6 to an alteration in mem-brane permeabiLlty with ultrasound during membrane excitahility. Caf-feine at 2.5-3,5 mM/L will block the ultrasound eEfect showing that the sarcoplasmic reticl~lum is an lntegral part oE the expression of the ultrasound enhancement. With caffeine and hypernatremia, we obtain an increase in diastolic tenslon rather than a decrease. This a]so shows that ~he sarcoplasmic reticulum is 1mplicated in the expression of the ultrasound effect. The ultrasonic production of myocardial enhancement can be produced through a number of modes. It is most rapid with contin-uous wave ultrasound but it may also be produced with improved efficiency
More partlcularly, the presen~ LnvelltLoll provi(les a method of improving cardlac performallce by appLying ultra.so~ d to the heart Ltself, either ~nternal.ly from ~q catlleter plflce(l wit.llin tlle heart, by ultrasoundIrradiatiorl appl:Led orl tlle surface of the bocly, or by ultra.qourlcl irradla~
tion applied directly ln contact with the heart. Ultrasourld -Ls also applied in combination w:ith an electrical deEibril.lator or pacemakerO
~le tnvention also relates to a metllod for application of ultrasound for well defined and selectable periods o~ time arranged to colnci.de wlth critical events in the cardiac cycle~
In addition, the lnvention relates to a method ~or the applica-tion of ultrasound ~or weLl defined and selectab].e periods of time relat-ed to critical events in the process of electrical def.LbrillationO
When the ultrasolllld waves produced by the transducers are a~justed such that their energy traverses the heart Ltself, the action of the waves can exert their e~fect by creating microthermal heating, micro-circnlation changes, stirring, stab:Le cav.Ltat-lon, microstreami.ng, or chemical effects~ The differential heating i.s produced because of the knowll property of ultrasound to be ab.sorbed by tissues according to their viscosities. Thus, membrane organelles within the heart absorb more energy than cytoplasmic components. It is thus expected that the sarco-plasmic reti.culum belng an internally located organelle within the heart would absorb energy and be heated preferentially before cytopla.sm.
Similarly, the sarcolemllla and its internal projections - the transverse and longitudinal transverse system would also be heated more thall extra-ceilulAr areas and cytoplasm. ~ecause of the differential heating, one woul.d expect bLo].ogic actLvitLes associated with these membranous compon-ents to be stimulated.
Thus, we find a linear relatlonsllip between myocardial enhance-ment between ().2 watt/cm2 an(l 2.() W/cm2 SAT~ of ultrasound exposllre~
This implies that when energy from ultra~soulld is applied wlthin a range to increase diEferential heatillg wltllin the l-Lmits commensllrate wlth bio--loglc activity (<44C~ we call fiel.ectlvely improve myocardla:l. performance.
~ur experimelltal evidence fihows that a portlon o~ the ~ILtrasoulld e~ect 3~
is produced via an increase o~ thc e~f-Lclellcy oE the excLtat-Lon-colltrac-tion coupling ~ystem. ~econd'ly, ~he actlorl poten~lal of ultrasound irradLated cells indLcates an imE)rovemellt in calcium transfer across the membrane in the ylateau phase. Both of these Eacts suggest that ultra-sound modLfies ~arcolemmal (external muscle membrane) characterir;tlc6.
The ultrasolllld eFfects are complete1y reverslble as opposed to conven-tional drug therapies.
Tl1e changes irl the "act~on potent-Lal" characteristics are con-si~stent wLth tlle view that membrane properties and, hence, biologlc prop-1~) erties are temporarily modlEied by ultrasound. Such changes would alterthe sodium-potassium ATPase~ This is seen in the resting nonexcited heart muscle as a rapid hyperpo]arisatLon of the membrarle potential which can be interpreted as an Lncrease in the activity of the Na~-K~~ATPase of sarcolemma. Seconclly, the rapid increase in the overshoot of the car-diac "action potential" with ultrasound point6 to an alteration in mem-brane permeabiLlty with ultrasound during membrane excitahility. Caf-feine at 2.5-3,5 mM/L will block the ultrasound eEfect showing that the sarcoplasmic reticl~lum is an lntegral part oE the expression of the ultrasound enhancement. With caffeine and hypernatremia, we obtain an increase in diastolic tenslon rather than a decrease. This a]so shows that ~he sarcoplasmic reticulum is 1mplicated in the expression of the ultrasound effect. The ultrasonic production of myocardial enhancement can be produced through a number of modes. It is most rapid with contin-uous wave ultrasound but it may also be produced with improved efficiency
2~ but at a sligllt loss in rapidity with pulsed ultrasound. Thus ultrasound pulsed in conjunction with an E~G sLgnal througll an appropriate circuit can aLso limit whole heart heatlng but produce the differential heatlng in the most advantageous portlon of the cardiac cycle to enhance the con-tractile behaviour of the heartO Pulsed, continoous wave, or a combina-tion of both, may be used in an predetermined or spontaneous mode toirradiate the lleart accordln~ to the c'Linic.1l conditLon nf the patient.
Mode of Appllcation Application in closed chest mode (extrathoralc applicat:Lon):
In such a case as where a patient e~hlbits cardiac Eailu-re and has a ventricll1ar tachycar<11a or ventrLculclr ELI)ri1'LatLon; u'Ltrasourld may ~e appl~ed by usin~ in the ~-Lrst instarlce, a trans~l1cer aimed at the heart and placed between the 4th and 5th r~bfi to the reglon o~ the heart~
Tl1e transducer i9 lleld firmly in place ag.~1llfit the chest and tran61nlssLon is alded withlr1 fl suitable couplillg mechallism. Tlle ultraso~nd Irradia-tion is either applle(l continuously or tLmed tr) the EKG slgnal via thecouE~ling clrc~lit. In this way, ultrasoun(l reaching the heart can effect the changes descrLbed in this app11cattor1~
In tlle case oE a fibrilLat~ng l~eart, the uLtrasoun(l may be applied throngh a transducer as above9 prlor ~o defibrlllation or may be applied as an integral part of the deftbrillatLng electronics as describ-ed in this application. The applicat~on of ultrasound preceding the defibrillation charge ~s ~sually as a cont~nuous wave. 11owever~ ~he con-trol circuit wi1l apply ultrasollnd in a pulsed mode as soon as an ~KG
slgnal is generated. ~1U~ tl1e ultrasotln~1 may be applied be~ore~ during and a~ter the defibrillation in order to enhance the recovery of the myocardium~
In the case where a pacemaker is used to program a heart beat cycle and inserted temporarily or permanently into a patient, the extrathoraic applicatton of ultrasounc1 may ~e used to augment the performance of a weakened heart. Preferably, ultrasound ptslses are ti~ed to coincide with a selected event ln the programmed beat cycle.
Open Chest Appllcation:
Where the heart of a patient is exposed due to a surgical intervention, such as in open heart surgery, the ultrasound may be applied by a transducer or transducers directly to the heart with a su-lt-able coupling medtum. This would be especially useful following open heart surgery where the clrculatLon of the blood and perfuslon of the body has been performed by mechanlcal means and must be transferred to the heart itself. The heart belng Ln a weakened condition from the period of anoxia and trauma, it cannot immediately perform the work necessary to sustain the circulatiol1 and may ultimately fai1. The use of ultrasound to augment cardiac performal1ce will result in a qulcker and more sustained recovery from the intra~operatLve state~
In the case where the heart wtll not resume its beat with or without paclng al1d reverts to random electrica1 ar1(1 mechanlcal actlvity (Elhrillat~oll) or ~a~l1ycard~a, ~he lI'`t` 0~ ul~:r;lsolll1(1 wLtl1 or wlthout tlle defibrillatory shock~, ~s shown in th~ apF-l1.c.1tion, wLll induce rhythmi-cal electrLcal mechanical activity, decre~sing the time to recover frorn tllis potentially catastrophic event(s).
In the case ~There a pat:Lent's heart can be weaned succesæfully froTn a mechanical pumplng device (heart-Lung machlne), the application of ltrasound directly to the heart ns de.~crLbed ln tni.s invention w:Lll assiLst in Lhe recovery ~hase of the immed1.ate post-operative cvndition.
In tl1e case where ultrasound wollld have to be applied by a Tniniature transducer to the heart, inserted via A catheter to the left or rigllt myocardium in a vein or artery, tl1e ultrasound probe may be insert-ed quickly if a patient i.n a critical state requires cardiac enhancement, such as in case of shock, Low volume syndrome (hemorrhage), nervous sys~
tem damage, brain damage or malFunc~ion, myocardiaL ischemi~, angina attack6. This may be applied in hospita1 or in an emergency vehicle, or in the fleld. Furthermore, the device can be used as a tool in the study of the :Eunctioning o~ the l1eart as an lnvestigative instrument.
Ultrasound must be applied to the heart in order to effect an improvement in the cardiac performance. The present invel1tion provides methods of applylng ultrasoulld having a frequency greater than 20 K11z and 2() up to 25 MH7. cluring critical periods of the cardiac cycle, without damage to Lntervening tissue or ~he l1eart itself in order to i~1prove cardiac contractility.
Accordingly, tl1e present invention provides an apparatus for ultrasonic enhancelTlent of cardiac contractility, said apparatus co~pris-ing means for detecti.ng a heart beat, means for generating ultra.soul1d,ancl ~eans for providlng timed pulses of ~sai.d ultrasoni.c energy, each said pulse to coincide witn a selected event in the cardiac cycle.
Brief Descriptlon oF tlle Drawlngs Figure 1 is a diagrammatlc iLlustratlol1 of the ultrasontc car~
Mode of Appllcation Application in closed chest mode (extrathoralc applicat:Lon):
In such a case as where a patient e~hlbits cardiac Eailu-re and has a ventricll1ar tachycar<11a or ventrLculclr ELI)ri1'LatLon; u'Ltrasourld may ~e appl~ed by usin~ in the ~-Lrst instarlce, a trans~l1cer aimed at the heart and placed between the 4th and 5th r~bfi to the reglon o~ the heart~
Tl1e transducer i9 lleld firmly in place ag.~1llfit the chest and tran61nlssLon is alded withlr1 fl suitable couplillg mechallism. Tlle ultraso~nd Irradia-tion is either applle(l continuously or tLmed tr) the EKG slgnal via thecouE~ling clrc~lit. In this way, ultrasoun(l reaching the heart can effect the changes descrLbed in this app11cattor1~
In tlle case oE a fibrilLat~ng l~eart, the uLtrasoun(l may be applied throngh a transducer as above9 prlor ~o defibrlllation or may be applied as an integral part of the deftbrillatLng electronics as describ-ed in this application. The applicat~on of ultrasound preceding the defibrillation charge ~s ~sually as a cont~nuous wave. 11owever~ ~he con-trol circuit wi1l apply ultrasollnd in a pulsed mode as soon as an ~KG
slgnal is generated. ~1U~ tl1e ultrasotln~1 may be applied be~ore~ during and a~ter the defibrillation in order to enhance the recovery of the myocardium~
In the case where a pacemaker is used to program a heart beat cycle and inserted temporarily or permanently into a patient, the extrathoraic applicatton of ultrasounc1 may ~e used to augment the performance of a weakened heart. Preferably, ultrasound ptslses are ti~ed to coincide with a selected event ln the programmed beat cycle.
Open Chest Appllcation:
Where the heart of a patient is exposed due to a surgical intervention, such as in open heart surgery, the ultrasound may be applied by a transducer or transducers directly to the heart with a su-lt-able coupling medtum. This would be especially useful following open heart surgery where the clrculatLon of the blood and perfuslon of the body has been performed by mechanlcal means and must be transferred to the heart itself. The heart belng Ln a weakened condition from the period of anoxia and trauma, it cannot immediately perform the work necessary to sustain the circulatiol1 and may ultimately fai1. The use of ultrasound to augment cardiac performal1ce will result in a qulcker and more sustained recovery from the intra~operatLve state~
In the case where the heart wtll not resume its beat with or without paclng al1d reverts to random electrica1 ar1(1 mechanlcal actlvity (Elhrillat~oll) or ~a~l1ycard~a, ~he lI'`t` 0~ ul~:r;lsolll1(1 wLtl1 or wlthout tlle defibrillatory shock~, ~s shown in th~ apF-l1.c.1tion, wLll induce rhythmi-cal electrLcal mechanical activity, decre~sing the time to recover frorn tllis potentially catastrophic event(s).
In the case ~There a pat:Lent's heart can be weaned succesæfully froTn a mechanical pumplng device (heart-Lung machlne), the application of ltrasound directly to the heart ns de.~crLbed ln tni.s invention w:Lll assiLst in Lhe recovery ~hase of the immed1.ate post-operative cvndition.
In tl1e case where ultrasound wollld have to be applied by a Tniniature transducer to the heart, inserted via A catheter to the left or rigllt myocardium in a vein or artery, tl1e ultrasound probe may be insert-ed quickly if a patient i.n a critical state requires cardiac enhancement, such as in case of shock, Low volume syndrome (hemorrhage), nervous sys~
tem damage, brain damage or malFunc~ion, myocardiaL ischemi~, angina attack6. This may be applied in hospita1 or in an emergency vehicle, or in the fleld. Furthermore, the device can be used as a tool in the study of the :Eunctioning o~ the l1eart as an lnvestigative instrument.
Ultrasound must be applied to the heart in order to effect an improvement in the cardiac performance. The present invel1tion provides methods of applylng ultrasoulld having a frequency greater than 20 K11z and 2() up to 25 MH7. cluring critical periods of the cardiac cycle, without damage to Lntervening tissue or ~he l1eart itself in order to i~1prove cardiac contractility.
Accordingly, tl1e present invention provides an apparatus for ultrasonic enhancelTlent of cardiac contractility, said apparatus co~pris-ing means for detecti.ng a heart beat, means for generating ultra.soul1d,ancl ~eans for providlng timed pulses of ~sai.d ultrasoni.c energy, each said pulse to coincide witn a selected event in the cardiac cycle.
Brief Descriptlon oF tlle Drawlngs Figure 1 is a diagrammatlc iLlustratlol1 of the ultrasontc car~
3() diac contracti:lity enhancirlg apparatus of this invention as it ~ould appear 11l use durLng he.lrt surgery.
Figure 2 i~ a sectlonal side elevat:Lonal. vlew of tl1e ultrasonlc transducer oF ~igure 1.
Figure 3 i~s a bottom plan vi.ew of all ultrs1~30~:1.c tra11sducer com ~)ined with an elee~trlc deFi.bri11ator.
Figure 4 Ls a cross-sectLonal .sl(le elevcl~orlal vle~ of the transdllcer of figure 3 taken alon~ l:he II.ne 4--l~ of fiKure 3.
Figure 5 is a schr.~natic draw:lng of tlle electrical controL clr-cuit oE the ernbo(limellt of ~igures l.'àn(l 2.
5Fig~lre 6 is a schem.ltlc drawing oE the control cLrcuit for the emboriiment of ~iKures 3 and 4.
Figure 7 is an illu.stration of tlle s-lgllal forms at dlfferent poLnts in the circuitry of flgure 5.
Figure 8 ls an illustrat:Lon of the sLgnal forms at diEferent points in the circuitry of figure 6.
Detailed Description Referri.ng now in detai'L to the drawings, the ultrasonic cardiac enhancer apparatus shown generally at 1() ill f:Lgure 1, :Eor use in intra-operative applicatLon, includes a transducer assembly, shown at 12. The ultrasoulld i.s produced by a pie7.0electric rnaterial or other means 14 mounted i.n a housing 16 of sui~able pLasti.c material. Tlle :i-'ront face of the houslng 16 ~as a menlbrane or cover 18 of material, such as latex rub-ber, to provide maximum transmission of ultrasound to the water coupling medium 2Q surrounding the transducer 12. l'he transducer 12 is centered in the transducer llousing 16 by ~eans of a transducer centering device 22 so that the ul~rasound energy exi~s frorn the transducer housing 16 in an unimpeded manner. The ultrasound leave.s the transducer housing 1 through an acoustic window 24 which provi.des very little disruption in tlle ultrasound beam. To maintaLn the transducer housing 16 and, particu-larly portions o~ the transducer housirlg 16 in contact with the patlentat body temperature, heatLng/cooling coils 28 are placed in the ~ater coupling mechanlsm surrounding the transducer.
The ultrasound irradiator used for closed chest application of ultrasound contains all the features descrLbed previously. In addition, a focussing e'lement 3~ of lucite (TM) or other ~u:Ltable material, Ls placed in front o~ the trans(lllcer 12 to focu~ the Illtrasound to a po:Lnt within the water batl~ coupli.llg medium ad~acerlt to the acoustlc w:Lndow 24.
This feature provides a narrow beam to pas.s tllrougll solall spacec, between bones yet the bcam e~p,llld~ to Lrradiate n l.arge port-Loll oi.- the heart. 'tn practice, the acou~tic wlndow 2~ in the tran.s(lllcer hollsin~ 16 mn~t be in physical con~acL with the heart 34 or the abc10n1e1l (not shown), respect-ively, in order that ultrasound may be tra1lsmitte(1. Either ~1ater, saline or an acoustic coupli1lg gel may he used to maintaln contact between the acoustic window 24 and the hody.
The -LrradLfltor for appllcatlo1ls Ln de~ibrillat-Lon Is shown gen-erally at 40 in ~figures 3 and 4. The Irradiatnr 40 consists of two main eleme1lts, an annular electrode 42 used to apply the electrical ener~y required for defibril]ation, and an ultrasound transducer 44 conslsting of several concentric rings of piezoelectric or other material, to pro~
duce ultrasoulld energy whLch may be directed into the body at an angLe dependent on tlle relatlve size of the concentric rLngs 44. The ultra-sound and electrical energy is inltiated hy a pushbutton 46 attached to the irradiator 40 whLch ls connected to the programrnable cdeflb-rillator circult, to be described below.
In practLce, tile ultrasound tra1lsducer defibrillator paddle 40 ls a,oplied to tlle chest in the region of an intercostal space overlylng the heart, physical contact ~ith the thorax ls rDade by the u~e of an acoustically and electrically conductive gel or a saline solution. The return defibrlllator electrode of conventional design ~not shown) is 2() placed as in conventiollaL practice. The type of fibrLllation to be treated ls seLected from the console and tl1e button on the handle pushed to activate the device. Further, the same instrurne1lt may be used for deflbrillat~on in an inoperative setttng with lower electrical energy appl:Led .
The ~system shown in figure 1 inclucles one of the ultrasound transducers described above, a radio fre~1ency electrical generator 50 which Is activated by a pulse ~odule 52 controlled to produce pulses allowing ultrasound from continuous wave to 3 ~ec pulses by a program-mable electrocardiogr;1ph (EKG) coinc-Ldence circuit 54, and a programmable deEibrlllator colncLdellce circuit 56.
A ~)ulse of ultrasonlc ener~y of varlable duration and intensLty related to critical events in the card-inc cycle may be prodl1cecl as shown in iigure 7. The ~K(; signal is acquired hy conventional EKG electrocdes 60 and 62 and ampli~lec1 by n hi~h ~ain a1npliEler 64 to prodl1ce the XKG
35 si,c~1lal 70, sho~Jn in flf~urf: 7. lhe 1~K(~ n;ll 7() i~s ~haped in a ~Lmin~
start r1Jlse 72 by a d1~crLmLna-or circuLt, showll genera:L1y at 74 ln flg.
5. T11e dLscrimir1atnr circ1lLt 74 ac.tLvates a ~el.ay circu:Lt 78, as .showll in fig. 5, whic11 1)rovides tl1e aE~I~rol)r1.ate de.l.ay interval. 80 (f:L~. 7) and may ~e adjnste(l alltomct:Lca1:Ly or extern;11.1.y to compensate ~or heart rate and cr1tical ev~llts witllin tlle heart ~ertain:l.rlg to the conditlon wl1ic}1 is being treated. Ttle del.ay intervA:L ge~1erat-Lng ci.rcui.t triggers an ul.tra-~sonlll1 ~atn~ pu.Lse circl.1it 82 whlcil produces ~ gflting waveform 84 of adJustabl.e widtll from 3 sec to Lnfinite length~ T}1e ~ating ~Javeform 84 is appLLed to radlo frequer1cy (r.f.) wave 86 in the pulse module circuit to generate a pul.sed radio frequency waveform 90. This pulsed r.f.
waveform 90 is amplified by the generator clrcult 92 and the amp].ified waveform 94 is applied to an ultrasonic transducer to produce ultrasonic energy at appropriate tisnes with respect to the cardiac cycle.
Furtl1er to the above circuits, a programmable defibrillator circuit (sho~l at 100 in figure 6) may he used for ultrasonic treatment tQ improve recovery irom de~ibrillation. Electrical de~ibrill.ation may he applied in the absence of EKG a~s occurs with ventricular fibrillation or synchronized ~o the EKG for inver.sion of atrial fibrillation by use of a mode switch 101. In eitl1er case, once tlle heart is beating, the ultra-sound may be applied at critical intervals withil1 the cardiac cycle asdescribed previously. The circuits descrlbed allow ultrasound to he applied ~or predetermined and accurate1.y controlled times with respect to the de~ibrillation pulse or accurately app~ied wLth respect to the con-traction of t)le heart and the elec~rical de~lbrillation pulse, in order to improve cardiac performance.
Tl1e operational se~luence 8hOWIl in figure 8 is init:iated by a short pulse 102 from the pushbutton switch 46 (figure 6) on the deflbril-lator 40. If EKG synchronizatiol1 has beer1 selected, tlle EKG signal 70, from patient electrodes 60 and 62, is formed into the discri.minated EKG
pulse 104. The rKG pulse 104 ln turn activates two delay circuits 108 and 110, the ultrasollnd timLng clrcult 114~ and tlle deflbrll].ator timing ci.rcuit 118 (shown in ~igure 6). The l.engLl1s oi tlle.se two del.ays 119 and 120 specify the order of occurrence of defibril1at:Lon ar1d ultrasound irradiat-Lon. Ir~ most ca.ses of vr.~ntrl.cl11.1r f:Lhri:Llation, appllcatLon of ultrasoulld :1s i.n-i.t~ated pr1Or to dei.ll-rl11atf.oll, where;1s l.n C.Ome ca.~es of - ~3 --atr-Lal fibrillatlon> the two evellts nee(l to be Losely syncllronized as descrihecl previously. The deFLhrLIlator clelay pulse 120 actuates a de-fLbrillator start clrcuit 118, whlcll sends a defLbrillator start pulse 121 to a deFLhrillator unit. Tlle ultrasound delay 108 actLvates an ultrasound gating circult, the output of which (125) is app]Led to the synchronized ultrasoulld gel-eratillg circn1ts (lescrLbed prevLollsly to produce ultrasoulld energy wllich Ls applled to the heart.
Figure 2 i~ a sectlonal side elevat:Lonal. vlew of tl1e ultrasonlc transducer oF ~igure 1.
Figure 3 i~s a bottom plan vi.ew of all ultrs1~30~:1.c tra11sducer com ~)ined with an elee~trlc deFi.bri11ator.
Figure 4 Ls a cross-sectLonal .sl(le elevcl~orlal vle~ of the transdllcer of figure 3 taken alon~ l:he II.ne 4--l~ of fiKure 3.
Figure 5 is a schr.~natic draw:lng of tlle electrical controL clr-cuit oE the ernbo(limellt of ~igures l.'àn(l 2.
5Fig~lre 6 is a schem.ltlc drawing oE the control cLrcuit for the emboriiment of ~iKures 3 and 4.
Figure 7 is an illu.stration of tlle s-lgllal forms at dlfferent poLnts in the circuitry of flgure 5.
Figure 8 ls an illustrat:Lon of the sLgnal forms at diEferent points in the circuitry of figure 6.
Detailed Description Referri.ng now in detai'L to the drawings, the ultrasonic cardiac enhancer apparatus shown generally at 1() ill f:Lgure 1, :Eor use in intra-operative applicatLon, includes a transducer assembly, shown at 12. The ultrasoulld i.s produced by a pie7.0electric rnaterial or other means 14 mounted i.n a housing 16 of sui~able pLasti.c material. Tlle :i-'ront face of the houslng 16 ~as a menlbrane or cover 18 of material, such as latex rub-ber, to provide maximum transmission of ultrasound to the water coupling medium 2Q surrounding the transducer 12. l'he transducer 12 is centered in the transducer llousing 16 by ~eans of a transducer centering device 22 so that the ul~rasound energy exi~s frorn the transducer housing 16 in an unimpeded manner. The ultrasound leave.s the transducer housing 1 through an acoustic window 24 which provi.des very little disruption in tlle ultrasound beam. To maintaLn the transducer housing 16 and, particu-larly portions o~ the transducer housirlg 16 in contact with the patlentat body temperature, heatLng/cooling coils 28 are placed in the ~ater coupling mechanlsm surrounding the transducer.
The ultrasound irradiator used for closed chest application of ultrasound contains all the features descrLbed previously. In addition, a focussing e'lement 3~ of lucite (TM) or other ~u:Ltable material, Ls placed in front o~ the trans(lllcer 12 to focu~ the Illtrasound to a po:Lnt within the water batl~ coupli.llg medium ad~acerlt to the acoustlc w:Lndow 24.
This feature provides a narrow beam to pas.s tllrougll solall spacec, between bones yet the bcam e~p,llld~ to Lrradiate n l.arge port-Loll oi.- the heart. 'tn practice, the acou~tic wlndow 2~ in the tran.s(lllcer hollsin~ 16 mn~t be in physical con~acL with the heart 34 or the abc10n1e1l (not shown), respect-ively, in order that ultrasound may be tra1lsmitte(1. Either ~1ater, saline or an acoustic coupli1lg gel may he used to maintaln contact between the acoustic window 24 and the hody.
The -LrradLfltor for appllcatlo1ls Ln de~ibrillat-Lon Is shown gen-erally at 40 in ~figures 3 and 4. The Irradiatnr 40 consists of two main eleme1lts, an annular electrode 42 used to apply the electrical ener~y required for defibril]ation, and an ultrasound transducer 44 conslsting of several concentric rings of piezoelectric or other material, to pro~
duce ultrasoulld energy whLch may be directed into the body at an angLe dependent on tlle relatlve size of the concentric rLngs 44. The ultra-sound and electrical energy is inltiated hy a pushbutton 46 attached to the irradiator 40 whLch ls connected to the programrnable cdeflb-rillator circult, to be described below.
In practLce, tile ultrasound tra1lsducer defibrillator paddle 40 ls a,oplied to tlle chest in the region of an intercostal space overlylng the heart, physical contact ~ith the thorax ls rDade by the u~e of an acoustically and electrically conductive gel or a saline solution. The return defibrlllator electrode of conventional design ~not shown) is 2() placed as in conventiollaL practice. The type of fibrLllation to be treated ls seLected from the console and tl1e button on the handle pushed to activate the device. Further, the same instrurne1lt may be used for deflbrillat~on in an inoperative setttng with lower electrical energy appl:Led .
The ~system shown in figure 1 inclucles one of the ultrasound transducers described above, a radio fre~1ency electrical generator 50 which Is activated by a pulse ~odule 52 controlled to produce pulses allowing ultrasound from continuous wave to 3 ~ec pulses by a program-mable electrocardiogr;1ph (EKG) coinc-Ldence circuit 54, and a programmable deEibrlllator colncLdellce circuit 56.
A ~)ulse of ultrasonlc ener~y of varlable duration and intensLty related to critical events in the card-inc cycle may be prodl1cecl as shown in iigure 7. The ~K(; signal is acquired hy conventional EKG electrocdes 60 and 62 and ampli~lec1 by n hi~h ~ain a1npliEler 64 to prodl1ce the XKG
35 si,c~1lal 70, sho~Jn in flf~urf: 7. lhe 1~K(~ n;ll 7() i~s ~haped in a ~Lmin~
start r1Jlse 72 by a d1~crLmLna-or circuLt, showll genera:L1y at 74 ln flg.
5. T11e dLscrimir1atnr circ1lLt 74 ac.tLvates a ~el.ay circu:Lt 78, as .showll in fig. 5, whic11 1)rovides tl1e aE~I~rol)r1.ate de.l.ay interval. 80 (f:L~. 7) and may ~e adjnste(l alltomct:Lca1:Ly or extern;11.1.y to compensate ~or heart rate and cr1tical ev~llts witllin tlle heart ~ertain:l.rlg to the conditlon wl1ic}1 is being treated. Ttle del.ay intervA:L ge~1erat-Lng ci.rcui.t triggers an ul.tra-~sonlll1 ~atn~ pu.Lse circl.1it 82 whlcil produces ~ gflting waveform 84 of adJustabl.e widtll from 3 sec to Lnfinite length~ T}1e ~ating ~Javeform 84 is appLLed to radlo frequer1cy (r.f.) wave 86 in the pulse module circuit to generate a pul.sed radio frequency waveform 90. This pulsed r.f.
waveform 90 is amplified by the generator clrcult 92 and the amp].ified waveform 94 is applied to an ultrasonic transducer to produce ultrasonic energy at appropriate tisnes with respect to the cardiac cycle.
Furtl1er to the above circuits, a programmable defibrillator circuit (sho~l at 100 in figure 6) may he used for ultrasonic treatment tQ improve recovery irom de~ibrillation. Electrical de~ibrill.ation may he applied in the absence of EKG a~s occurs with ventricular fibrillation or synchronized ~o the EKG for inver.sion of atrial fibrillation by use of a mode switch 101. In eitl1er case, once tlle heart is beating, the ultra-sound may be applied at critical intervals withil1 the cardiac cycle asdescribed previously. The circuits descrlbed allow ultrasound to he applied ~or predetermined and accurate1.y controlled times with respect to the de~ibrillation pulse or accurately app~ied wLth respect to the con-traction of t)le heart and the elec~rical de~lbrillation pulse, in order to improve cardiac performance.
Tl1e operational se~luence 8hOWIl in figure 8 is init:iated by a short pulse 102 from the pushbutton switch 46 (figure 6) on the deflbril-lator 40. If EKG synchronizatiol1 has beer1 selected, tlle EKG signal 70, from patient electrodes 60 and 62, is formed into the discri.minated EKG
pulse 104. The rKG pulse 104 ln turn activates two delay circuits 108 and 110, the ultrasollnd timLng clrcult 114~ and tlle deflbrll].ator timing ci.rcuit 118 (shown in ~igure 6). The l.engLl1s oi tlle.se two del.ays 119 and 120 specify the order of occurrence of defibril1at:Lon ar1d ultrasound irradiat-Lon. Ir~ most ca.ses of vr.~ntrl.cl11.1r f:Lhri:Llation, appllcatLon of ultrasoulld :1s i.n-i.t~ated pr1Or to dei.ll-rl11atf.oll, where;1s l.n C.Ome ca.~es of - ~3 --atr-Lal fibrillatlon> the two evellts nee(l to be Losely syncllronized as descrihecl previously. The deFLhrLIlator clelay pulse 120 actuates a de-fLbrillator start clrcuit 118, whlcll sends a defLbrillator start pulse 121 to a deFLhrillator unit. Tlle ultrasound delay 108 actLvates an ultrasound gating circult, the output of which (125) is app]Led to the synchronized ultrasoulld gel-eratillg circn1ts (lescrLbed prevLollsly to produce ultrasoulld energy wllich Ls applled to the heart.
Claims (8)
1. An apparatus for ultrasonic enhancement of cardiac contractil-ity, comprising:
- means for detecting or programming a heart beat cycle, - means for generating ultrasound, - means for providing pulses of said ultrasound, and - means to time each said pulse to coincide with a selected event in the cardiac contraction cycle.
- means for detecting or programming a heart beat cycle, - means for generating ultrasound, - means for providing pulses of said ultrasound, and - means to time each said pulse to coincide with a selected event in the cardiac contraction cycle.
2. The apparatus of claim 1 wherein said means for detecting a heart beat cycle is an electrocardiograph.
3. The apparatus of claim 1 wherein said means for generating ultrasound is combined with one electrode of a pair of defibrillator electrodes.
4. The apparatus of claim 1 wherein a focussing element is pro-vided on said ultrasound generating means, for directing the ultrasound to pass between adjacent ribs in a patient's chest and then diverge to contact a greater area of the heart.
5. The apparatus of claim 1 wherein the ultrasound generating means is located in, or feeds into, a catheter probe.
6. The apparatus of claim 1 wherein a signal is acquired by EKG
electrodes and said means for providing timed pulses includes a discrim-inator circuit, a delay circuit, a ultrasound gating pulse circuit, and a radio frequency pulse module circuit for providing pulsed radio frequency to said means for generating ultrasound.
electrodes and said means for providing timed pulses includes a discrim-inator circuit, a delay circuit, a ultrasound gating pulse circuit, and a radio frequency pulse module circuit for providing pulsed radio frequency to said means for generating ultrasound.
7. The apparatus of claim 1 wherein the ultrasound generator is adapted to generate ultrasound of frequency within the range of about 20 KHz to about 25 MHz.
8. An apparatus for heart defibrillation and ultrasonic enhance-ment of cardiac contractility comprising means for generating ultrasound combined with one electrode of a pair of electrical defibrillator electrodes.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA000416992A CA1199371A (en) | 1982-12-03 | 1982-12-03 | Ultrasonic enhancement of cardiac contractility synchronised with ecg event or defibrillation pulse |
EP83307205A EP0112082A3 (en) | 1982-12-03 | 1983-11-25 | Method and device for enhancement of cardiac contractility |
US06/793,787 US4651716A (en) | 1982-12-03 | 1985-11-01 | Method and device for enhancement of cardiac contractility |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA000416992A CA1199371A (en) | 1982-12-03 | 1982-12-03 | Ultrasonic enhancement of cardiac contractility synchronised with ecg event or defibrillation pulse |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1199371A true CA1199371A (en) | 1986-01-14 |
Family
ID=4124078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000416992A Expired CA1199371A (en) | 1982-12-03 | 1982-12-03 | Ultrasonic enhancement of cardiac contractility synchronised with ecg event or defibrillation pulse |
Country Status (3)
Country | Link |
---|---|
US (1) | US4651716A (en) |
EP (1) | EP0112082A3 (en) |
CA (1) | CA1199371A (en) |
Families Citing this family (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3777327D1 (en) * | 1986-10-24 | 1992-04-16 | Siemens Ag | LIQUID CIRCUIT FOR A DEVICE FOR THE CRUSHING OF CONCRETE IN THE BODY OF A LIVING BEING. |
US4820260A (en) * | 1986-11-10 | 1989-04-11 | Hayden Steven M | Method and apparatus for extravascular treatment of red blood cells |
DE3814743C2 (en) * | 1988-04-30 | 1994-01-27 | Wolf Gmbh Richard | Device for dissolving concrements in a body cavity |
US5291894A (en) * | 1989-11-14 | 1994-03-08 | Nagy Lajos Z | Apparatus for treating a patient with acoustic waves |
NL8902809A (en) * | 1989-11-14 | 1991-06-03 | Lajos Zoltan Nagy | DEVICE FOR TREATING WITH ACOUSTIC WAVES AND DIAGNOSTIZING A PATIENT. |
US7167748B2 (en) * | 1996-01-08 | 2007-01-23 | Impulse Dynamics Nv | Electrical muscle controller |
US8321013B2 (en) | 1996-01-08 | 2012-11-27 | Impulse Dynamics, N.V. | Electrical muscle controller and pacing with hemodynamic enhancement |
US8825152B2 (en) * | 1996-01-08 | 2014-09-02 | Impulse Dynamics, N.V. | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
IL125424A0 (en) | 1998-07-20 | 1999-03-12 | New Technologies Sa Ysy Ltd | Pacing with hemodynamic enhancement |
IL125136A (en) * | 1996-01-08 | 2003-07-31 | Impulse Dynamics Nv | Electrical cardiac muscle controller method and apparatus |
US9289618B1 (en) | 1996-01-08 | 2016-03-22 | Impulse Dynamics Nv | Electrical muscle controller |
US9713723B2 (en) | 1996-01-11 | 2017-07-25 | Impulse Dynamics Nv | Signal delivery through the right ventricular septum |
US6415178B1 (en) * | 1996-09-16 | 2002-07-02 | Impulse Dynamics N.V. | Fencing of cardiac muscles |
US7840264B1 (en) | 1996-08-19 | 2010-11-23 | Mr3 Medical, Llc | System and method for breaking reentry circuits by cooling cardiac tissue |
US7908003B1 (en) | 1996-08-19 | 2011-03-15 | Mr3 Medical Llc | System and method for treating ischemia by improving cardiac efficiency |
DE59712045D1 (en) * | 1996-08-22 | 2004-12-02 | Storz Medical Ag Kreuzlingen | DEVICE FOR TREATING THE HEART |
US6110098A (en) | 1996-12-18 | 2000-08-29 | Medtronic, Inc. | System and method of mechanical treatment of cardiac fibrillation |
EP1121176A1 (en) * | 1998-10-15 | 2001-08-08 | Cardio Technologies, Inc. | Passive defibrillation electrodes for use with cardiac assist device |
US7211054B1 (en) * | 1998-11-06 | 2007-05-01 | University Of Rochester | Method of treating a patient with a neurodegenerative disease using ultrasound |
US6152882A (en) * | 1999-01-26 | 2000-11-28 | Impulse Dynamics N.V. | Apparatus and method for chronic measurement of monophasic action potentials |
WO2000044442A2 (en) * | 1999-01-28 | 2000-08-03 | Ultra Cure Ltd. | An ultrasound system and methods utilizing same |
US6206843B1 (en) | 1999-01-28 | 2001-03-27 | Ultra Cure Ltd. | Ultrasound system and methods utilizing same |
JP2002536040A (en) * | 1999-02-02 | 2002-10-29 | トランサージカル,インコーポレイテッド | High intensity focused ultrasound applicator in the body |
EP2208782B1 (en) * | 1999-02-04 | 2017-05-31 | Pluristem Ltd. | Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
US20040249421A1 (en) * | 2000-09-13 | 2004-12-09 | Impulse Dynamics Nv | Blood glucose level control |
US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US8346363B2 (en) * | 1999-03-05 | 2013-01-01 | Metacure Limited | Blood glucose level control |
US8019421B2 (en) * | 1999-03-05 | 2011-09-13 | Metacure Limited | Blood glucose level control |
US8700161B2 (en) * | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
US6263242B1 (en) | 1999-03-25 | 2001-07-17 | Impulse Dynamics N.V. | Apparatus and method for timing the delivery of non-excitatory ETC signals to a heart |
US6298269B1 (en) | 1999-04-19 | 2001-10-02 | Cardiac Pacemakers, Inc. | Cardiac rhythm management system with ultrasound for autocapture or other applications |
US6223072B1 (en) | 1999-06-08 | 2001-04-24 | Impulse Dynamics N.V. | Apparatus and method for collecting data useful for determining the parameters of an alert window for timing delivery of ETC signals to a heart under varying cardiac conditions |
US6233487B1 (en) | 1999-06-08 | 2001-05-15 | Impulse Dynamics N.V. | Apparatus and method for setting the parameters of an alert window used for timing the delivery of ETC signals to a heart under varying cardiac conditions |
AU1049901A (en) | 1999-10-25 | 2001-05-08 | Impulse Dynamics N.V. | Cardiac contractility modulation device having anti-arrhythmic capabilities and a method of operating thereof |
US6993385B1 (en) * | 1999-10-25 | 2006-01-31 | Impulse Dynamics N.V. | Cardiac contractility modulation device having anti-arrhythmic capabilities and a method of operating thereof |
US7027863B1 (en) | 1999-10-25 | 2006-04-11 | Impulse Dynamics N.V. | Device for cardiac therapy |
US7335169B2 (en) * | 2000-08-24 | 2008-02-26 | Timi 3 Systems, Inc. | Systems and methods for delivering ultrasound energy at an output power level that remains essentially constant despite variations in transducer impedance |
US20030069526A1 (en) * | 2000-08-24 | 2003-04-10 | Timi 3 Systems, Inc. | Applicators that house and support ultrasound transducers for transcutaneous delivery of ultrasound energy |
US20020072690A1 (en) * | 2000-08-24 | 2002-06-13 | Timi 3 | Transportable systems for applying ultrasound energy to the thoracic cavity |
US20020072691A1 (en) * | 2000-08-24 | 2002-06-13 | Timi 3 Systems, Inc. | Systems and methods for applying ultrasonic energy to the thoracic cavity |
US20020082529A1 (en) * | 2000-08-24 | 2002-06-27 | Timi 3 Systems, Inc. | Systems and methods for applying pulsed ultrasonic energy |
US7220232B2 (en) * | 2000-08-24 | 2007-05-22 | Timi 3 Systems, Inc. | Method for delivering ultrasonic energy |
JP2004509671A (en) * | 2000-08-24 | 2004-04-02 | ティミ 3 システムズ, インコーポレイテッド | System and method for applying ultrasonic energy |
US20040073115A1 (en) * | 2000-08-24 | 2004-04-15 | Timi 3 Systems, Inc. | Systems and methods for applying ultrasound energy to increase tissue perfusion and/or vasodilation without substantial deep heating of tissue |
US7241270B2 (en) * | 2000-08-24 | 2007-07-10 | Timi 3 Systems Inc. | Systems and methods for monitoring and enabling use of a medical instrument |
US7369890B2 (en) * | 2000-11-02 | 2008-05-06 | Cardiac Pacemakers, Inc. | Technique for discriminating between coordinated and uncoordinated cardiac rhythms |
US6689117B2 (en) * | 2000-12-18 | 2004-02-10 | Cardiac Pacemakers, Inc. | Drug delivery system for implantable medical device |
US20050283197A1 (en) * | 2001-04-10 | 2005-12-22 | Daum Douglas R | Systems and methods for hypotension |
US6912420B2 (en) | 2001-04-10 | 2005-06-28 | Cardiac Pacemakers, Inc. | Cardiac rhythm management system for hypotension |
US6907288B2 (en) | 2001-04-10 | 2005-06-14 | Cardiac Pacemakers, Inc. | Cardiac rhythm management system adjusting rate response factor for treating hypotension |
US7166467B2 (en) * | 2001-07-23 | 2007-01-23 | Senesco Technologies, Inc. | Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis |
US6748271B2 (en) * | 2001-07-27 | 2004-06-08 | Cardiac Pacemakers, Inc. | Method and system for treatment of neurocardiogenic syncope |
US7191000B2 (en) | 2001-07-31 | 2007-03-13 | Cardiac Pacemakers, Inc. | Cardiac rhythm management system for edema |
DE60218708D1 (en) | 2001-09-24 | 2007-04-19 | Cosmetic Technologies Llc | DEVICE AND METHOD FOR INDIVIDUAL COMPOSITION OF COSMETICS |
US8573263B2 (en) | 2001-09-24 | 2013-11-05 | Cosmetic Technologies, Llc | Apparatus and method for custom cosmetic dispensing |
IL148299A (en) * | 2002-02-21 | 2014-04-30 | Technion Res & Dev Foundation | Ultrasound cardiac stimulator |
EP1347609B1 (en) * | 2002-03-22 | 2007-11-21 | STMicroelectronics S.r.l. | Method and apparatus for decoding Manchester-encoded signals |
US7228175B2 (en) | 2002-05-15 | 2007-06-05 | Cardiac Pacemakers, Inc. | Cardiac rhythm management systems and methods using acoustic contractility indicator |
US7089055B2 (en) * | 2002-06-28 | 2006-08-08 | Cardiac Pacemakers, Inc. | Method and apparatus for delivering pre-shock defibrillation therapy |
AU2009210402A1 (en) * | 2002-07-24 | 2009-09-10 | Timi 3 Systems, Inc. | Systems and methods for monitoring and enabling use of a medical instrument |
US7229423B2 (en) * | 2003-02-05 | 2007-06-12 | Timi 3 System, Inc | Systems and methods for applying audible acoustic energy to increase tissue perfusion and/or vasodilation |
CA2442352A1 (en) * | 2002-09-26 | 2004-03-26 | Reg Macquarrie | Poly-(vinyl alcohol) based meat processing films |
US7226422B2 (en) * | 2002-10-09 | 2007-06-05 | Cardiac Pacemakers, Inc. | Detection of congestion from monitoring patient response to a recumbent position |
US7627373B2 (en) * | 2002-11-30 | 2009-12-01 | Cardiac Pacemakers, Inc. | Method and apparatus for cell and electrical therapy of living tissue |
US20040158289A1 (en) * | 2002-11-30 | 2004-08-12 | Girouard Steven D. | Method and apparatus for cell and electrical therapy of living tissue |
US20080208084A1 (en) * | 2003-02-05 | 2008-08-28 | Timi 3 Systems, Inc. | Systems and methods for applying ultrasound energy to increase tissue perfusion and/or vasodilation without substantial deep heating of tissue |
WO2004070396A2 (en) | 2003-02-10 | 2004-08-19 | N-Trig Ltd. | Touch detection for a digitizer |
US11439815B2 (en) | 2003-03-10 | 2022-09-13 | Impulse Dynamics Nv | Protein activity modification |
US7840262B2 (en) * | 2003-03-10 | 2010-11-23 | Impulse Dynamics Nv | Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue |
WO2004112886A2 (en) * | 2003-06-17 | 2004-12-29 | Ebr Systems, Inc. | Methods and systems for vibrational treatment of cardiac arrhythmias |
US7006864B2 (en) * | 2003-06-17 | 2006-02-28 | Ebr Systems, Inc. | Methods and systems for vibrational treatment of cardiac arrhythmias |
US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US7184830B2 (en) * | 2003-08-18 | 2007-02-27 | Ebr Systems, Inc. | Methods and systems for treating arrhythmias using a combination of vibrational and electrical energy |
EP1667767A1 (en) * | 2003-08-22 | 2006-06-14 | Medtronic, Inc. | Method and apparatus for cardiac resuscitation |
US8734368B2 (en) | 2003-09-04 | 2014-05-27 | Simon Fraser University | Percussion assisted angiogenesis |
US20050080469A1 (en) * | 2003-09-04 | 2005-04-14 | Larson Eugene A. | Treatment of cardiac arrhythmia utilizing ultrasound |
US8870796B2 (en) | 2003-09-04 | 2014-10-28 | Ahof Biophysical Systems Inc. | Vibration method for clearing acute arterial thrombotic occlusions in the emergency treatment of heart attack and stroke |
US8721573B2 (en) | 2003-09-04 | 2014-05-13 | Simon Fraser University | Automatically adjusting contact node for multiple rib space engagement |
CA2439667A1 (en) * | 2003-09-04 | 2005-03-04 | Andrew Kenneth Hoffmann | Low frequency vibration assisted blood perfusion system and apparatus |
US20050070962A1 (en) * | 2003-09-30 | 2005-03-31 | Ebr Systems, Inc. | Methods and systems for treating heart failure with vibrational energy |
US7050849B2 (en) * | 2003-11-06 | 2006-05-23 | Ebr Systems, Inc. | Vibrational therapy device used for resynchronization pacing in a treatment for heart failure |
US8352031B2 (en) * | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
US11779768B2 (en) | 2004-03-10 | 2023-10-10 | Impulse Dynamics Nv | Protein activity modification |
DE202004009224U1 (en) * | 2004-06-14 | 2004-08-12 | Isra Vision Systems Ag | Sensor for measuring the surface of an object |
US7765001B2 (en) * | 2005-08-31 | 2010-07-27 | Ebr Systems, Inc. | Methods and systems for heart failure prevention and treatments using ultrasound and leadless implantable devices |
WO2006020189A2 (en) * | 2004-07-19 | 2006-02-23 | Barthomolew Julie R | Customized retail point of sale dispensing methods |
US7387610B2 (en) | 2004-08-19 | 2008-06-17 | Cardiac Pacemakers, Inc. | Thoracic impedance detection with blood resistivity compensation |
EP1827571B1 (en) | 2004-12-09 | 2016-09-07 | Impulse Dynamics NV | Protein activity modification |
US8060219B2 (en) * | 2004-12-20 | 2011-11-15 | Cardiac Pacemakers, Inc. | Epicardial patch including isolated extracellular matrix with pacing electrodes |
US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
EP1835964B1 (en) * | 2004-12-21 | 2016-03-09 | EBR Systems, Inc. | Leadless cardiac system for pacing and arrhythmia treatment |
US7558631B2 (en) * | 2004-12-21 | 2009-07-07 | Ebr Systems, Inc. | Leadless tissue stimulation systems and methods |
WO2006069327A2 (en) * | 2004-12-21 | 2006-06-29 | Ebr Systems, Inc. | Implantable transducer devices |
US7590445B1 (en) * | 2005-02-01 | 2009-09-15 | Pacesetter, Inc. | Indirect mechanical medical therapy system |
US9821158B2 (en) | 2005-02-17 | 2017-11-21 | Metacure Limited | Non-immediate effects of therapy |
WO2006097934A2 (en) * | 2005-03-18 | 2006-09-21 | Metacure Limited | Pancreas lead |
US7603170B2 (en) * | 2005-04-26 | 2009-10-13 | Cardiac Pacemakers, Inc. | Calibration of impedance monitoring of respiratory volumes using thoracic D.C. impedance |
EP1898991B1 (en) * | 2005-05-04 | 2016-06-29 | Impulse Dynamics NV | Protein activity modification |
US7907997B2 (en) * | 2005-05-11 | 2011-03-15 | Cardiac Pacemakers, Inc. | Enhancements to the detection of pulmonary edema when using transthoracic impedance |
US7340296B2 (en) | 2005-05-18 | 2008-03-04 | Cardiac Pacemakers, Inc. | Detection of pleural effusion using transthoracic impedance |
DE102005031116B4 (en) * | 2005-07-04 | 2012-04-12 | Siemens Ag | Shockwave system |
US7702392B2 (en) * | 2005-09-12 | 2010-04-20 | Ebr Systems, Inc. | Methods and apparatus for determining cardiac stimulation sites using hemodynamic data |
US8343049B2 (en) | 2006-08-24 | 2013-01-01 | Cardiac Pacemakers, Inc. | Physiological response to posture change |
US7948215B2 (en) * | 2007-04-19 | 2011-05-24 | Hadronex, Inc. | Methods and apparatuses for power generation in enclosures |
US8718773B2 (en) | 2007-05-23 | 2014-05-06 | Ebr Systems, Inc. | Optimizing energy transmission in a leadless tissue stimulation system |
US7953493B2 (en) | 2007-12-27 | 2011-05-31 | Ebr Systems, Inc. | Optimizing size of implantable medical devices by isolating the power source |
EP2265166B1 (en) | 2008-03-25 | 2020-08-05 | EBR Systems, Inc. | Temporary electrode connection for wireless pacing systems |
US20100016911A1 (en) | 2008-07-16 | 2010-01-21 | Ebr Systems, Inc. | Local Lead To Improve Energy Efficiency In Implantable Wireless Acoustic Stimulators |
US8934975B2 (en) | 2010-02-01 | 2015-01-13 | Metacure Limited | Gastrointestinal electrical therapy |
US9980741B2 (en) * | 2011-06-13 | 2018-05-29 | P Tech, Llc | Methods and systems for controlling an ultrasonic handpiece based on tuning signals |
EP3302169B1 (en) | 2015-06-08 | 2021-07-21 | Cosmetic Technologies, LLC | Automated delivery system of a cosmetic sample |
US10507009B2 (en) | 2017-10-05 | 2019-12-17 | EchoNous, Inc. | System and method for fusing ultrasound with additional signals |
EP3731922B1 (en) | 2017-10-23 | 2024-02-21 | DataFeel Inc. | Communication devices, methods, and systems |
CN109157245A (en) * | 2018-09-11 | 2019-01-08 | 北京东方惠尔医疗科技有限公司 | A kind of ultrasound electrocardio defibrillation device |
KR20210106982A (en) | 2018-10-08 | 2021-08-31 | 에코너스 인코퍼레이티드 | DEVICE INCLUDING ULTRASOUND, AUSCULTATION, AND AMBIENT NOISE SENSORS |
US11934583B2 (en) | 2020-10-30 | 2024-03-19 | Datafeel Inc. | Wearable data communication apparatus, kits, methods, and systems |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE654673C (en) * | 1935-12-15 | 1937-12-24 | Siemens Reiniger Werke Akt Ges | Device for the treatment of bodies with ultrasonic waves |
FR1535612A (en) * | 1967-06-26 | 1968-08-09 | Medical device for controlled cardiac massages | |
US3651801A (en) * | 1969-09-29 | 1972-03-28 | Saul Kullok | Apparatus for effecting massages synchronously with the heart activity |
US3720199A (en) * | 1971-05-14 | 1973-03-13 | Avco Corp | Safety connector for balloon pump |
US3735756A (en) * | 1971-06-23 | 1973-05-29 | Medco Products Co Inc | Duplex ultrasound generator and combined electrical muscle stimulator |
AT333938B (en) * | 1973-01-31 | 1976-12-27 | Herwig Dipl Ing Dr Techn Thoma | DEVICE FOR THE AUTOMATIC CONTROL OF AN ELECTROPNEUMATIC HEART-SYNCHRONOUS CIRCULATION PUMP |
US3871360A (en) * | 1973-07-30 | 1975-03-18 | Brattle Instr Corp | Timing biological imaging, measuring, and therapeutic timing systems |
US3970076A (en) * | 1974-04-18 | 1976-07-20 | Dornier System Gmbh | Apparatus for heart stimulation |
US3951140A (en) * | 1974-11-13 | 1976-04-20 | Indianapolis Center For Advanced Research | Ultrasonic therapy apparatus and method |
US3954098A (en) * | 1975-01-31 | 1976-05-04 | Dick Donald E | Synchronized multiple image tomographic cardiography |
US4016871A (en) * | 1975-03-06 | 1977-04-12 | Peter Schiff | Electronic synchronizer-monitor system for controlling the timing of mechanical assistance and pacing of the heart |
US4094310A (en) * | 1976-10-04 | 1978-06-13 | American Optical Corporation | Apparatus for enhanced display of physiological waveforms and for defibrillation |
US4204524A (en) * | 1977-11-07 | 1980-05-27 | Dov Jaron | Method and apparatus for controlling cardiac assist device |
US4198963A (en) * | 1978-10-19 | 1980-04-22 | Michigan Instruments, Inc. | Cardiopulmonary resuscitator, defibrillator and monitor |
US4216766A (en) * | 1979-09-07 | 1980-08-12 | The United States Of America As Represented By The Secretary Of The Navy | Treatment of body tissue by means of internal cavity resonance |
US4303075A (en) * | 1980-02-11 | 1981-12-01 | Mieczyslaw Mirowski | Method and apparatus for maximizing stroke volume through atrioventricular pacing using implanted cardioverter/pacer |
EP0038080B1 (en) * | 1980-04-16 | 1985-08-28 | Medtronic, Inc. | Patient interactive stimulator |
US4399703A (en) * | 1980-10-16 | 1983-08-23 | Dymax Corporation | Ultrasonic transducer and integral drive circuit therefor |
US4462402A (en) * | 1982-11-15 | 1984-07-31 | Minnesota Mining And Manufacturing Company | Method and anchor for anchoring |
-
1982
- 1982-12-03 CA CA000416992A patent/CA1199371A/en not_active Expired
-
1983
- 1983-11-25 EP EP83307205A patent/EP0112082A3/en not_active Withdrawn
-
1985
- 1985-11-01 US US06/793,787 patent/US4651716A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US4651716A (en) | 1987-03-24 |
EP0112082A2 (en) | 1984-06-27 |
EP0112082A3 (en) | 1985-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1199371A (en) | Ultrasonic enhancement of cardiac contractility synchronised with ecg event or defibrillation pulse | |
KR102124422B1 (en) | High-low intensity focused ultrasound treatment apparatus | |
US8603086B2 (en) | Method for preventing thrombus formation | |
US5393296A (en) | Method for the medical treatment of pathologic bone | |
US3968802A (en) | Cautery protection circuit for a heart pacemaker | |
EP0617981B1 (en) | Mechanical defibrillation | |
US5284136A (en) | Dual indifferent electrode pacemaker | |
US3893462A (en) | Bioelectrochemical regenerator and stimulator devices and methods for applying electrical energy to cells and/or tissue in a living body | |
US3970076A (en) | Apparatus for heart stimulation | |
RU2113237C1 (en) | Device and method for applying cosmetic treatment of human body by removing fat tissue mass | |
US20080009885A1 (en) | Skin and adipose tissue treatment by nonfocalized opposing side shock waves | |
EP0450229A2 (en) | Dual indifferent electrode | |
GB1321364A (en) | Method and apparatus for high frequency electric surgery | |
JPH06125915A (en) | Catheter type medical instrument | |
Langberg et al. | The effects of extracorporeal shock wave lithotripsy on pacemaker function | |
JP2001136599A (en) | Ultrasonic-wave generation source for medical treatment and ultrasonic-wave medical treating equipment | |
Fetter et al. | Effects of extracorporeal shock wave lithotripsy on single chamber rate response and dual chamber pacemakers | |
US5058590A (en) | Apparatus for dispersing fluids for dissolution or concretions in a bodily cavity | |
JP2000060813A (en) | Method and device for automatically generating electric helper signal | |
US20240032983A1 (en) | Electronic apparatus for delivering coherent sine burst irreversible electroporation energy to a biological tissue | |
JPS6247359A (en) | Ultrasonic bone stimulating apparatus | |
JPS6247358A (en) | Ultrasonic stimulating apparatus | |
JPH067362A (en) | Device for shock wave medical treatment | |
JPH04117957A (en) | Calculus crushing device | |
RU2050862C1 (en) | Device for treating tachyarrhythmia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |